Study of SGLT2 inhibitor effects on liver sugar production
Treatments studied
Part of Hormones & metabolism clinical trials.
This trial tests how stopping a type 2 diabetes medication called an SGLT2 inhibitor affects the liver's production of sugar and ketones. It may help understand better ways to manage diabetes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have type 2 diabetes.
- You are between 30 and 75 years old.
- Your body mass index (BMI) is between 21 and 45.
- Your HbA1c (average blood sugar over 3 months) is between 7.0% and 11%.
- Your kidney function is good (eGFR above 60).
- You are not currently taking insulin or thiazolidinediones (TZDs).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests how a type of diabetes medicine called SGLT2 inhibitors affects how the liver makes sugar. It may help researchers better understand how to manage blood sugar in people with type 2 diabetes.
This study looks at how stopping a common diabetes drug (SGLT2 inhibitor) affects the body's risk of a serious condition called ketoacidosis. It may help understand who is most at risk and how to prevent it.
This trial tests how combining a ketone supplement with certain diabetes medicines affects blood sugar and ketone levels. It may help adults with type 2 diabetes who are not on insulin or certain other drugs.
This study tests how a drug called canagliflozin (an SGLT2 inhibitor) affects kidney function in people with type 2 diabetes. It involves two kidney biopsies to see how the drug works inside your kidneys, aiming to better protect kidney health.
This trial compares two medications, dapagliflozin and empagliflozin, to see which works better and is safer for people with type 2 diabetes and a high body mass index (BMI). If you are an adult with type 2 diabetes and a BMI of 23 or higher, this study might help find a treatment that also supports weight loss.
This trial compares adding a new pill (cofrogliptin) to increasing your current metformin dose, for people whose blood sugar is still too high despite taking an SGLT2 inhibitor and a low dose of metformin. The goal is to see which option works better and is safer.
Hear when a new Type 2 diabetes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.